Greenup Street Wealth Management LLC Boosts Stake in Zoetis Inc. (NYSE:ZTS)

Greenup Street Wealth Management LLC lifted its stake in Zoetis Inc. (NYSE:ZTS) by 5.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,075 shares of the company’s stock after purchasing an additional 413 shares during the period. Greenup Street Wealth Management LLC’s holdings in Zoetis were worth $1,578,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of ZTS. Asset Dedication LLC lifted its stake in Zoetis by 4.8% in the second quarter. Asset Dedication LLC now owns 1,174 shares of the company’s stock worth $204,000 after purchasing an additional 54 shares during the last quarter. Forza Wealth Management LLC lifted its stake in Zoetis by 1.8% in the second quarter. Forza Wealth Management LLC now owns 3,313 shares of the company’s stock worth $574,000 after purchasing an additional 58 shares during the last quarter. L. Roy Papp & Associates LLP lifted its stake in Zoetis by 2.8% in the second quarter. L. Roy Papp & Associates LLP now owns 2,221 shares of the company’s stock worth $385,000 after purchasing an additional 60 shares during the last quarter. Grove Bank & Trust lifted its stake in Zoetis by 0.5% in the third quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock worth $2,298,000 after purchasing an additional 61 shares during the last quarter. Finally, Angeles Wealth Management LLC lifted its stake in Zoetis by 3.8% in the first quarter. Angeles Wealth Management LLC now owns 1,702 shares of the company’s stock worth $288,000 after purchasing an additional 62 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Price Performance

Shares of ZTS opened at $191.00 on Friday. The company has a market cap of $87.15 billion, a price-to-earnings ratio of 36.80, a price-to-earnings-growth ratio of 2.99 and a beta of 0.89. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The company has a 50 day moving average of $188.82 and a two-hundred day moving average of $176.80.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. Zoetis’s revenue was up 8.3% compared to the same quarter last year. During the same period last year, the firm earned $1.41 earnings per share. As a group, analysts predict that Zoetis Inc. will post 5.83 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.90%. Zoetis’s dividend payout ratio (DPR) is 33.14%.

Analyst Ratings Changes

A number of brokerages have recently commented on ZTS. Piper Sandler raised their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. BTIG Research raised their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Stifel Nicolaus raised their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, JPMorgan Chase & Co. raised their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.